Effectiveness of robust optimization in volumetric modulated arc therapy using 6 and 10 MV flattening filter-free beam therapy planning for lung stereotactic body radiation therapy with a breath-hold technique.


Journal

Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611

Informations de publication

Date de publication:
06 Jul 2020
Historique:
received: 27 11 2019
revised: 27 01 2020
pubmed: 6 5 2020
medline: 9 7 2021
entrez: 6 5 2020
Statut: ppublish

Résumé

We investigated the feasibility of a robust optimization with 6 MV X-ray (6X) and 10 MV X-ray (10X) flattening filter-free (FFF) beams in a volumetric modulated arc therapy (VMAT) plan for lung stereotactic body radiation therapy (SBRT) using a breath-holding technique. Ten lung cancer patients were selected. Four VMAT plans were generated for each patient; namely, an optimized plan based on the planning target volume (PTV) margin and a second plan based on a robust optimization of the internal target volume (ITV) with setup uncertainties, each for the 6X- and 10X-FFF beams. Both optimized plans were normalized by the percentage of the prescription dose covering 95% of the target volume (D95%) to the PTV (1050 cGy × 4 fractions). All optimized plans were evaluated using perturbed doses by specifying user-defined shifted values from the isocentre. The average perturbed D99% doses to the ITV, compared to the nominal plan, decreased by 369.1 (6X-FFF) and 301.0 cGy (10X-FFF) for the PTV-based optimized plan, and 346.0 (6X-FFF) and 271.6 cGy (10X-FFF) for the robust optimized plan, respectively. The standard deviation of the D99% dose to the ITV were 163.6 (6X-FFF) and 158.9 cGy (10X-FFF) for the PTV-based plan, and 138.9 (6X-FFF) and 128.5 cGy (10X-FFF) for the robust optimized plan, respectively. Robust optimized plans with 10X-FFF beams is a feasible method to achieve dose certainty for the ITV for lung SBRT using a breath-holding technique.

Identifiants

pubmed: 32367109
pii: 5829022
doi: 10.1093/jrr/rraa026
pmc: PMC7336549
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

575-585

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

Références

Phys Med. 2017 Aug;40:115-121
pubmed: 28784572
Med Phys. 2010 Feb;37(2):505-15
pubmed: 20229859
Phys Med. 2017 Dec;44:188-195
pubmed: 28130055
Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):420-5
pubmed: 23523183
J ICRU. 2010 Apr;10(1):27-40
pubmed: 24173325
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):660-9
pubmed: 21281896
J Appl Clin Med Phys. 2014 Jan 06;15(1):4202
pubmed: 24423832
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Med Phys. 2014 Aug;41(8):081707
pubmed: 25086517
J Neurosurg. 2000 Dec;93 Suppl 3:219-22
pubmed: 11143252
Jpn J Clin Oncol. 2017 Jan 9;47(3):277-281
pubmed: 28073946
Med Phys. 2014 Mar;41(3):031709
pubmed: 24593713
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):190-5
pubmed: 22929858
Med Phys. 2006 Oct;33(10):3874-900
pubmed: 17089851
Med Phys. 2013 Jul;40(7):071718
pubmed: 23822422
Radiat Oncol. 2014 Oct 16;9:223
pubmed: 25319444
Med Phys. 2014 Jun;41(6):061501
pubmed: 24877795
Phys Med. 2017 Dec;44:113-122
pubmed: 28647449
Med Phys. 2008 May;35(5):1926-31
pubmed: 18561668
Med Phys. 2011 Mar;38(3):1672-84
pubmed: 21520880
Phys Med. 2016 Nov;32(11):1405-1414
pubmed: 27756535
J Radiat Res. 2013 Jan;54(1):140-5
pubmed: 22951318
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1228-37
pubmed: 21129855
J Appl Clin Med Phys. 2017 Sep;18(5):104-116
pubmed: 28786213
J Clin Oncol. 2010 Dec 10;28(35):5153-9
pubmed: 21041709
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):685-92
pubmed: 18164849
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):603-11
pubmed: 10524412
Phys Med. 2017 Dec;44:157-162
pubmed: 27890568
Radiother Oncol. 2010 Dec;97(3):437-42
pubmed: 21074878
Pract Radiat Oncol. 2019 Jan;9(1):38-48
pubmed: 30138747
Phys Med. 2016 Apr;32(4):600-6
pubmed: 27061871
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):172-180
pubmed: 26700711

Auteurs

Hideharu Miura (H)

Hiroshima High-Precision Radiotherapy Cancer Center.
Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University.

Shuichi Ozawa (S)

Hiroshima High-Precision Radiotherapy Cancer Center.
Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University.

Yoshiko Doi (Y)

Hiroshima High-Precision Radiotherapy Cancer Center.
Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University.

Minoru Nakao (M)

Hiroshima High-Precision Radiotherapy Cancer Center.
Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University.

Katsumaro Kubo (K)

Hiroshima High-Precision Radiotherapy Cancer Center.

Masahiko Kenjo (M)

Hiroshima High-Precision Radiotherapy Cancer Center.
Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University.

Yasushi Nagata (Y)

Hiroshima High-Precision Radiotherapy Cancer Center.
Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH